Search results

Filters

  • Journals
  • Authors
  • Keywords
  • Date
  • Type

Search results

Number of results: 1
items per page: 25 50 75
Sort by:
Download PDF Download RIS Download Bibtex

Abstract

Malignancies of the hematopoietic system frequently are associated with severe cytopenias requiring transfusions of blood components. Refusal of blood components by Jehovah’s Witnesses (JW) produces challenges to treatment. In this report we describe the outcome of hematological malignancies of JW patients treated without transfusions. Altogether, eight JW, diagnosed 1994–2015, 6 (75%) females, the median age at diagnosis 40 years (range, 20–78), were included into the analysis. The diagnoses were: acute lymphoblastic leukemia (2, 25%), acute myeloid leukemia (2, 25%), non-Hodgkin’s lymphomas (4, 50%). One patient died without treatment while the remaining 7 patients received treatment, including imatinib in 1 patient with BCR-ABL1+ acute lymphoblastic leukemia. Five (62.5%) patients received erythropoiesis stimulating agents. Median hemoglobin concentration at diagnosis was 8.7 g/dL (range, 6.3–13.1), and it decreased to 3.2 g/dL (range, 2.6–9.3) during first-line treatment. Median platelet count at diagnosis was 52 × 109/L (range, 15–392). All patients became thrombocytopenic upon treatment reaching median platelet count 8 × 109/L (range, 2–85). Five patients developed respiratory failure. Anemia contributed substantially to the death of 3 out of 6 patients (50%). One patient (17%) developed central nervous system bleeding in the course of thrombocytopenia. Objective response rate was 43%, with 29% complete remissions after first-line treatment. Despite the median overall survival of 15.3 months (95% CI, 0.2–52.2), all but one acute leukemia patients succumbed shortly after the diagnosis. To conclude, the outcome of JW treated because of hematological malignancies without blood transfusions is very dismal, nevertheless, selected patients can obtain complete remissions. Anemia contributes significantly to the death of JW.
Go to article

Bibliography

1. Bouchnita A., Eymard N., Moyo T.K., Koury M.J., Volpert V.: Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis. Am J Hematol. 2016; 91 (4): 371– 378. doi: 10.1002/ajh.24291.
2. Wang Y., Gao A., Zhao H., et al.: Leukemia cell infiltration causes defective erythropoiesis partially through MIP-1alpha/CCL3. Leukemia. 2016; 30 (9): 1897–1908. doi: 10.1038/leu.2016.81.
3. Bohlius J., Bohlke K., Castelli R., et al.: Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. J Clin Oncol. 2019; 37 (15): 1336–1351. doi: 10.1200/JCO.18.02142.
4. Schiffer C.A., Bohlke K., Delaney M., et al.: Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018; 36 (3): 283–299. doi: 10.1200/JCO.2017.76.1734.
5. Drozd-Sokolowska J.E., Wiktor-Jedrzejczak W.: Factors determining the risk of severe (WHO grades 3 and 4) hemorrhage in hematologic patients. Transfus Apher Sci. 2011; 44: 129–134. doi: 10.1016/j. transci.2011.01.004.
6. Rodgers G.M., Gilreath J.A., Alwan L., et al.: Cancer- and Chemotherapy Induced Anemia. NCCN Clinical Practice Guidelines in Oncology. https://www.nccn.org/professionals/physician_gls/f_guidelines. asp#anemia: NCCN; 2016.
7. Laszlo D., Agazzi A., Goldhirsch A., et al.: Tailored therapy of adult acute leukaemia in Jehovah’s Witnesses: unjustified reluctance to treat. Eur J Haematol. 2004; 72 (4): 264–267. doi: 10.1111/ j.0902-4441.2003.00211.x.
8. Chojnowski K., Janus A., Blizniewska K., Robak M., Trelinski J.: Long-lasting extreme anemia during the therapy of acute lymphoblastic leukemia in a Jehovah’s Witness patient. Transfusion. 2016; 56 (10): 2438–2442. doi: 10.1111/trf.13703.
9. Mazza P., Palazzo G., Amurri B., Cervellera M., Rizzo C., Maggi A.: Acute leukemia in Jehovah’s Witnesses: a challenge for hematologists. Haematologica. 2000; 85: 1221–1222.
10. Brown N.M., Keck G., Ford P.A.: Acute myeloid leukemia in Jehovah Witnesses. Leuk Lymphoma. 2008; 49 (4): 817–820. doi: 10.1080/10428190801911670.
11. Cullis J.O., Duncombe A.S., Dudley J.M., Lumley H.S., Apperley J.F., Smith A.G.: Acute leukaemia in Jehovah’s Witnesses. Br J Haematol. 1998; 100 (4): 664–668. doi: 10.1046/j.1365-2141.1998.00634.x.
12. Wilop S., Osieka R.: Antineoplastic chemotherapy in Jehovah’s Witness patients with acute myelogenous leukemia refusing blood products — a matched pair analysis. Hematology. 2018; 23 (6): 324–329. doi: 10.1080/10245332.2017.
13. Ford P.A., Grant S.J., Mick R., Keck G.: Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah’s Witnesses. J Clin Oncol. 2015; 33 (15): 1674–1679. doi: 10.1200/JCO.2014.57.9912.
14. Agapidou A., Vakalopoulou S., Papadopoulou T., Chadjiaggelidou C., Garypidou V.: Successful Treatment of Severe Anemia using Erythropoietin in a Jehovah Witness with Non-Hodgkin Lymphoma. Hematol Rep. 2014; 6 (4): 5600. doi: 10.4081/hr.2014.5600.
15. Yamamoto Y., Kawashima A., Kashiwagi E., Ogata K.: A Jehovah’s Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions. Case Rep Hematol. 2014; 2014: 141260. doi: 10.1155/2014/141260.
16. Garelius H., Grund S., Stockelberg D.: Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah’s Witness with acute monocytic leukemia. Clin Case Rep. 2015; 3 (5): 287–290. doi: 10.1002/ccr3.212.
17. Bareford D., Odeh B., Narayanan S., Wiltshire S.: Remission induction in a Jehovah’s witness patient with acute myeloid leukaemia using gemtuzumab ozogamicin. Transfus Med. 2005; 15 (5): 445–448. doi: 10.1111/j.1365-3148.2005.00611.x.
18. Fujisawa S., Naito K., Matsuoka T., Kobayashi M.: Complete remission induced by gemtuzumab ozogamicin in a Jehovah’s Witness patient with acute myelogenous leukemia. Int J Hematol. 2007; 85 (5): 418–420. doi: 10.1532/IJH97.07018.
19. Donahue L.L., Shapira I., Shander A., Kolitz J., Allen S., Greenburg G.: Management of acute anemia in a Jehovah’s Witness patient with acute lymphoblastic leukemia with polymerized bovine hemoglobin- based oxygen carrier: a case report and review of literature. Transfusion. 2010; 50 (7): 1561– 1567. doi: 10.1111/j.1537-2995.2010.02603.x.
Go to article

Authors and Affiliations

Joanna Ewa Drozd-Sokołowska
1
Anna Waszczuk-Gajda
1
Jadwiga Dwilewicz-Trojaczek
1
Alicja Walesiak
1
Monika Krzyżanowska
1
Monika Paluszewska
1
Jolanta Wieczorek
1
Wiesław Wiktor-Jędrzejczak
1

  1. Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Poland

This page uses 'cookies'. Learn more